Učitavanje...
Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer
Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent years, however, immune checkpoint inhibitors have emerged as promising therapeutic agents in non‐small cell lung cancer (NSCLC). To date, the best characterized and most therapeutically relevant immune checkpoin...
Spremljeno u:
| Izdano u: | Oncologist |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wiley-Blackwell
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5313266/ https://ncbi.nlm.nih.gov/pubmed/27534574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0189 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|